From Brazil comes the latest peer-reviewed study1 showing the benefits of Ivermectin in treating COVID-19. This study highlights what the author terms a “dose response” effect, where the more you take the more benefits you get.
And the benefits are substantial, cutting mortality risk by more than 90%.
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.
Expect corporate media to dismiss or denigrate the study. Heaven forbid people should have access to low-cost therapeutics to fend off COVID-19.
Kerr L, Baldi F, Lobo R, et al. (August 31, 2022) Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects. Cureus 14(8): e28624. doi:10.7759/cureus.28624
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.